tradingkey.logo

Procept Biorobotics Corp

PRCT
View Detailed Chart
35.200USD
-0.730-2.03%
Market hours ETQuotes delayed by 15 min
1.96BMarket Cap
LossP/E TTM

Procept Biorobotics Corp

35.200
-0.730-2.03%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.03%

5 Days

+0.28%

1 Month

-3.54%

6 Months

-37.49%

Year to Date

-56.28%

1 Year

-63.60%

View Detailed Chart

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Procept Biorobotics Corp's Score

Industry at a Glance

Industry Ranking
13 / 210
Overall Ranking
65 / 4623
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Buy
Current Rating
65.182
Target Price
+76.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Procept Biorobotics Corp Highlights

StrengthsRisks
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 199.27% year-on-year.
Fairly Valued
The company’s latest PE is -23.16, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.59M shares, decreasing 2.13% quarter-over-quarter.
Held by Wasatch Global Investors
Star Investor Wasatch Global Investors holds 188.69K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Procept Biorobotics Corp Info

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
CompanyProcept Biorobotics Corp
CEOMr. Larry L. Wood
Websitehttps://www.procept-biorobotics.com/
KeyAI